S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
Log in

NovelStem International Stock Forecast, Price & News

-0.03 (-30.00 %)
(As of 11/25/2020 12:00 AM ET)
Today's Range
Now: $0.07
50-Day Range
MA: $0.07
52-Week Range
Now: $0.07
Volume197 shs
Average Volume38,127 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
NovelStem International Corp. focuses on developing and commercialization of diagnostic technology that can predict patients' resistance to chemotherapy allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. It has a collaboration agreement with NewStem Ltd. for stem-cell technology platform in cancer immunotherapy and COVID-19 resistance. The company was formerly known as Hollywood Media Corp. and changed its name to NovelStem International Corp. in September 2018 as a result of its business focus shift from advertising services to stem cell-based diagnostics for cancer chemotherapies. The company was founded in 1993 and is headquartered in Boca Raton, Florida.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.00 out of 5 stars

Industry, Sector and Symbol

Industry Retail stores, not elsewhere classified
Current SymbolOTCMKTS:NSTM



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable
-0.03 (-30.00 %)
(As of 11/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NSTM News and Ratings via Email

Sign-up to receive the latest news and ratings for NSTM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

NovelStem International (OTCMKTS:NSTM) Frequently Asked Questions

What stocks does MarketBeat like better than NovelStem International?

Wall Street analysts have given NovelStem International a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but NovelStem International wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting NovelStem International?

NovelStem International saw a drop in short interest in October. As of October 30th, there was short interest totaling 100 shares, a drop of 92.3% from the October 15th total of 1,300 shares. Based on an average trading volume of 7,400 shares, the short-interest ratio is currently 0.0 days.
View NovelStem International's Short Interest

Who are some of NovelStem International's key competitors?

Who are NovelStem International's key executives?

NovelStem International's management team includes the following people:
  • Mr. Mitchell Rubenstein, Co-Founder & Director (Age 66, Pay $665.2k)
  • Mr. David Collins, Investor Relations Firm, Catalyst IR

What is NovelStem International's stock symbol?

NovelStem International trades on the OTCMKTS under the ticker symbol "NSTM."

How do I buy shares of NovelStem International?

Shares of NSTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NovelStem International's stock price today?

One share of NSTM stock can currently be purchased for approximately $0.07.

What is NovelStem International's official website?

The official website for NovelStem International is www.novelstem.com.

How can I contact NovelStem International?

NovelStem International's mailing address is 2255 GLADES RD STE 237 W, BOCA RATON FL, 33431. The company can be reached via phone at 410-654-3315 or via email at [email protected]

This page was last updated on 11/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.